INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,612 | +39.0% | 23,076 | +14.1% | 1.81% | +23.3% |
| Q2 2023 | $16,269 | -2.7% | 20,230 | 0.0% | 1.47% | +4.8% |
| Q1 2023 | $16,727 | -4.0% | 20,230 | -11.0% | 1.40% | +10.1% |
| Q4 2022 | $17,422 | -99.9% | 22,730 | +18.2% | 1.28% | +31.7% |
| Q3 2022 | $14,382,000 | +129.0% | 19,230 | +96.3% | 0.97% | +115.6% |
| Q2 2022 | $6,281,000 | +20.0% | 9,795 | +22.7% | 0.45% | -12.5% |
| Q1 2021 | $5,236,000 | +16.5% | 7,985 | -99.9% | 0.51% | -16.6% |
| Q4 2020 | $4,494,000 | -12.7% | 7,485,000 | 0.0% | 0.62% | -45.0% |
| Q3 2020 | $5,145,000 | +261.3% | 7,485,000 | +277.1% | 1.12% | +101.8% |
| Q2 2020 | $1,424,000 | +65.0% | 1,985,000 | +101.5% | 0.55% | +13.1% |
| Q1 2020 | $863,000 | -81.3% | 985,000 | -71.7% | 0.49% | -78.8% |
| Q4 2019 | $4,611,000 | +2.9% | 3,485,000 | -30.1% | 2.31% | -9.0% |
| Q3 2019 | $4,480,000 | +80.2% | 4,985,000 | +99.4% | 2.54% | +76.1% |
| Q2 2019 | $2,486,000 | – | 2,500,000 | – | 1.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |